Glaxo Taps Astex for Fragment-Based Discovery Deal Worth At Least $33 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Astex expects up to an additional $61 million in near-term milestones, and avoids the option-based structure that GlaxoSmithKline prefers.
You may also be interested in...
Astex Finds A Suitable Home As Otsuka Subsidiary
The California/U.K.-based biotech has announced plans to be acquired by Japanese pharma Otsuka in a deal that will please shareholders and provide its suitor with a slew of revenue-generating opportunities including a mid-stage pipeline, a platform technology and royalty streams.
Astex Finds A Suitable Home As Otsuka Subsidiary
The California/U.K.-based biotech has announced plans to be acquired by Japanese pharma Otsuka in a deal that will please shareholders and provide its suitor with a slew of revenue-generating opportunities including a mid-stage pipeline, a platform technology and royalty streams.
SuperGen Buys U.K.'s Astex, Building Cash-Rich Oncology Play
The deal brings private Astex a long-sought NASDAQ listing and beefs up cash-rich SuperGen's lackluster pipeline.